Neurologist and Duke ALS Clinic Director Richard Bedlack “stitches strength” for his patients, showing the powers of hope.

Inhibition of a cellular stress response may be a therapeutic target for ALS type 8 related to mutations in the VAPB gene, a ...

• In June 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced that the FDA granted Fast Track designation to AMX0114, ...

Study shows how ALS-linked mutations disrupt the protein TDP-43 at the atomic level, preventing it from executing its ...

Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig's disease, is an incurable neurological disorder affecting motor ...

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose ...

Exposure to rhodamine B (RhB), a toxic fluorescent dye, causes neurodegeneration, symptoms that resemble ALS, and molecular ...

Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig's disease, is an incurable neurological disorder affecting motor ...

Apathy and depression are the most prevalent neuropsychiatric symptoms in amyotrophic lateral sclerosis (ALS).1-3 Although ...

Dampening the integrated stress response (IRS) in motor neurons may be a valid therapeutic approach in patients with an inherited form of ALS.